Nakayama, Takahiro
Sagara, Yasuaki
Takashima, Tsutomu
Matsunami, Nobuki
Masuda, Norikazu
Miyoshi, Yasuo
Taguchi, Tetsuya
Aono, Toyokazu
Ito, Toshikazu
Kagimura, Tatsuo
Noguchi, Shinzaburo
Funding for this research was provided by:
Taiho Pharmaceutical
Article History
Received: 16 January 2018
Accepted: 12 February 2018
First Online: 21 February 2018
Compliance with ethical standards
:
: Takahiro Nakayama has received honoraria from Chugai Pharmaceutical, AstraZeneca, Taiho Pharmaceutical, and Novartis Pharma. Norikazu Masuda has received honoraria from AstraZeneca and Chugai. Yasuo Miyoshi has received honoraria and research funding from AstraZeneca and Taiho. Shinzaburo Noguchi has received honoraria from AstraZeneca, Taiho, Chugai, Novartis, Takeda, and Daiichi-Sankyo, has received research funding from AstraZeneca, Taiho, Pfizer, Chugai, Eisai, Takeda, and Daiichi-Sankyo, and is an advisor for Taiho, AstraZeneca, and Novartis. The other authors declare that they have no potential conflicts of interest. Foundation for Biomedical Research and Innovation has received research grant from AstraZeneca.
: The study was conducted in accordance with the ethical standards established in the 1964 Declaration of Helsinki and its later amendments. The study was approved by the institutional review board of each study site, and all patients participating in the study provided informed consent before enrollment.